par Gompel, Anne;Barlow, David;Rozenberg, Serge 
;Skouby, Sven O;EMAS Executive Committee,
Référence Maturitas, 56, 2, page (227-229)
Publication Publié, 2007-02
;Skouby, Sven O;EMAS Executive Committee, Référence Maturitas, 56, 2, page (227-229)
Publication Publié, 2007-02
Article révisé par les pairs
| Résumé : | This new statement from EMAS presents the findings reported in recent publications from both WHI trials. In general, the reports do not necessitate a revision of the current EMAS advice. They provide further insight into the ongoing controversy around the possibility that hormone therapy (HT) in the form of estrogen (E) alone or estrogen-progestogen (EP) may influence risk of breast cancer differently. They confirm that the increase of breast cancer diagnosis under EP is only significant after a cumulative use of more than 5 years but suggest that there is no increased risk by E within 10 years. |
